Insight Molecular Diagnostics Inc. — Director's Dealing 2024

Jun 24, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2024-06-20

Reporting Person: James Andrea S. (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-06-20	Option to Purchase Common Stock	$2.87	A	200000	Acquired		Common Stock (200000)	Direct
2024-06-20	Restricted Stock Units	$	A	100000	Acquired		Common Stock (100000)	Direct

Footnotes

F1: Granted on June 20, 2024 (the "Grant Date"), but such award is subject to shareholder approval of an increase in the number of shares available for issuance under the Oncocyte 2018 Equity Incentive Plan. Following such shareholder approval, an additional Form 4 will be filed with respect to the grant in accordance with pursuant to Section 16(a) of the Securities Exchange Act of 1934, as amended.

F2: The Option shall vest as follows, subject to the Reporting Person's continued compliance with any restrictive covenants by which the Reporting Person may be bound and continuous service as an employee of the Issuer or a Subsidiary from June 17, 2024, through the applicable vesting date: (A) twenty-five percent (25%) of the shares subject to the Option will vest and thereby become exercisable upon the one-year anniversary of the Grant Date, and (B) 75% of the shares subject to the Option will vest in thirty-six (36) substantially equal monthly installments thereafter.

F3: See Exhibit 99 attached hereto.